Choose your own adventure: Door A says start mammograms at 40 and keep the scanner on a steady rhythm. Door B says 50 is the sweet spot for most average-risk women. Door C opens into a conference room where doctors, statisticians, and people with dense breasts are all arguing at once, which is honestly the most realistic option.
That last door is what this Annals of Internal Medicine Q&A is really about. Jennifer Kearney-Strouse’s piece is not a splashy lab discovery with glowing cells and dramatic microscope music. It is something more adult and, in its own way, weirder: a front-row seat to how medicine tries to make peace with uncertainty. The American College of Physicians is focusing on what it calls appropriate breast cancer screening, which is a polite phrase for a very impolite problem: how do you catch dangerous cancers early without sending huge numbers of healthy people into the haunted house of false alarms, extra biopsies, and overdiagnosis?
The Scanner Is Not a Crystal Ball
Breast cancer screening sounds simple until you actually look under the hood. Mammography helps find cancers earlier, and earlier detection can save lives. But screening is not a magic tricorder from the future. It also turns up suspicious-looking findings that end up being nothing, and sometimes it finds very slow-growing cancers that might never have caused trouble in a person’s lifetime. That is overdiagnosis, which is one of those medical terms that sounds fake until you realize it can lead to very real surgery, radiation, stress, and bills.
The ACP guidance statement that sits behind this Q&A lands in a careful middle lane. For average-risk women ages 50 to 74, it recommends biennial mammography. For ages 40 to 49, it says the choice should depend on risk, values, and tolerance for the tradeoffs. For women 75 and older, it leans toward a conversation about whether routine screening still makes sense. And for dense breasts, ACP says consider 3D mammography, but do not automatically jump to screening MRI or ultrasound for everyone (Qaseem et al., 2026).
Why Everyone Is Arguing in the Hallway
Here is the spicy part. ACP’s stance is not the only one in town. The U.S. Preventive Services Task Force updated its recommendation in 2024 to support biennial screening for women ages 40 to 74, while still saying the evidence is not strong enough yet to settle the question of routine supplemental MRI or ultrasound for dense breasts (USPSTF, 2024). That sounds tidy on paper. Real life is less tidy.
Dense breast tissue is the chaos goblin in this story. It is common, it slightly raises breast cancer risk, and it makes mammograms harder to read because both dense tissue and tumors can show up white. Looking for a white threat inside a white background is not ideal. It is the imaging equivalent of trying to spot a polar bear in a blizzard while someone keeps handing you new guidelines.
Modeling studies suggest there may be a benefit to adding MRI for some women with dense breasts, but the tradeoff is more false-positive recalls and more benign biopsies (Sprague et al., 2024). A 2023 Radiology systematic review found MRI detected more additional cancers than ultrasound, tomosynthesis, or automated ultrasound in women with dense breasts and negative mammograms, but the authors also noted that mortality benefit and cost-effectiveness still need better proof (Hussein et al., 2023).
The Plot Twist Is Personalization
The old model of screening treats age like the main control panel. That is useful, but blunt. Newer work is trying to make screening more like precision navigation and less like using one map for every planet.
The WISDOM trial is a good example. Instead of giving everyone the same annual schedule, it used genetic testing, risk scores, and clinical factors to sort women into different screening paths. The risk-based approach was noninferior to annual screening for more advanced cancers, used fewer mammograms overall, but did not cut biopsy rates as hoped (Esserman et al., 2026). Translation: the future may be smarter, but it is not yet a neat little app that solves everything while you sip a lager.
Why This Matters Outside the Journal Club
This Q&A matters because screening policy is not abstract. It shapes insurance coverage, clinic workflows, anxiety levels, and whether a woman with dense breasts leaves a mammogram feeling reassured or like she has been handed a puzzle box with no instructions. It also matters because not all groups experience breast cancer equally. Black women are more likely to die from breast cancer and are more likely to be diagnosed with aggressive disease at younger ages, which means any “average-risk” guidance needs a side of humility and a large warning label about equity (USPSTF, 2024).
So no, this is not the flashiest oncology story of the year. No laser swords. No mutant receptor reveal. Just a complicated question about when to scan, how often, and for whom. But that is exactly why it is worth your attention. Cancer screening is one of those places where modern medicine looks less like a superhero movie and more like engineers trying to keep a spaceship running while the manual is still being written.
References
- Kearney-Strouse J. Q&A: ACP focuses on appropriate screening for breast cancer. Ann Intern Med. 2026. https://doi.org/10.7326/ANNALS-26-01726-IM
- Qaseem A, Crandall CJ, Mustafa RA, et al. Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2). Ann Intern Med. 2026. https://doi.org/10.7326/ANNALS-25-05116
- US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-1930. https://doi.org/10.1001/jama.2024.5534
- Sprague BL, Trentham-Dietz A, Chapman CH, et al. Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density. JAMA Intern Med. 2024;184(10):1222-1231. https://doi.org/10.1001/jamainternmed.2024.4224
- Hussein H, Abbas E, Keshavarzi S, et al. Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis. Radiology. 2023;306(3):e221785. https://doi.org/10.1148/radiol.221785
- Esserman LJ, Fiscalini AS, Naeim A, et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA. 2026;335(9):763-774. https://doi.org/10.1001/jama.2025.24784
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.